Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey

References

• Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):iii116–iii123.
   Google Scholar
• Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75(3):329–338.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis- results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493.
   PubMed Web of Science ®Google Scholar
• Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090.
   PubMed Web of Science ®Google Scholar
• Schwensen JF, Clemmensen A, Sand C, et al. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: a retrospective multicenter study. Dermatol Ther. 2017;30(6):10.
   Web of Science ®Google Scholar
• Momose M, Asahina A, Umezawa Y, et al. Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: a single-center experience. J Dermatol. 2018;45(3):318–321.
   PubMed Web of Science ®Google Scholar
• Körber A, Thaçi D, von Kiedrowski R, et al. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. J Eur Acad Dermatol Venereol. 2018;32(3):411–419.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, De Simone C, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18(7):727–735.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Ighani A, Zhou LL, et al. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. J Eur Acad Dermatol Venereol. 2018;32(1):e32–e34.
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Tsentemeidou A, Vakirlis E, et al. Secukinumab survival and long-term efficacy in patients with plaque psoriasis: real-life data from a tertiary hospital in Greece. J Eur Acad Dermatol Venereol. 2019;33(2):e82–e84.
   PubMed Web of Science ®Google Scholar
• Tsentemeidou A, Sotiriou E, Vakirlis E, et al. Real-life efficacy and safety of secukinumab: results from a tertiary hospital in Greece. J Eur Acad Dermatol Venereol. 2019;33(2):e50–e51.
   PubMed Web of Science ®Google Scholar
• Ortiz-Salvador JM, Saneleuterio-Temporal M, Magdaleno-Tapial J, et al. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J Am Acad Dermatol. 2019;81(2):427–432.
   PubMed Web of Science ®Google Scholar
• Notario J, Deza G, Vilarrasa E, et al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatolog Treat. 2019;30(5):424–429.
   PubMed Web of Science ®Google Scholar
• Rompoti N, Katsimbri P, Kokkalis G, et al. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study . Dermatol Ther. 2019;32(5):e13006.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Balato A, Conrad C, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat. 2019;31(5):476–483.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2020;20(2):173–182.
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Nakamura M, et al. Anti-IL-17 agents for psoriasis: a review of phase III data. J Drugs Dermatol. 2016;15(3):311–316.
   PubMedGoogle Scholar
• Ferrières L, Konstantinou MP, Bulai Livideanu C, et al. Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. Clin Exp Dermatol. 2019;44(7):e230–e234.
   PubMed Web of Science ®Google Scholar
• Ger TY, Huang YH, Hui RC, Tsai TF, et al. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis. 2019;10:2040622319843756.
   Web of Science ®Google Scholar
• Bruin G, Loesche C, Nyirady J, et al. Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis. J Clin Pharmacol. 2017;57(7):876–885.
   PubMed Web of Science ®Google Scholar
• Phung M, Georgakopoulos JR, Ighani A, et al. Secukinumab dose optimization in adult psoriasis patients: a retrospective, multicenter case series. JAAD Case Rep. 2018;4(4):310–313.
   PubMedGoogle Scholar
• Phung M, Ighani A, Georgakopoulos JR, et al. Off-label high-dose secukinumab for the treatment of moderate-to-severe psoriasis. J Cutan Med Surg. 2019;23(4):391–393.
   PubMed Web of Science ®Google Scholar
• Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304–315.
   PubMed Web of Science ®Google Scholar
• Megna M, Di Costanzo L, Argenziano G, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19(8):855–861.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519.
   PubMed Web of Science ®Google Scholar
• Yanagihara S, Sugita K, Yoshida Y, et al. Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy. Eur J Dermatol. 2017;27(2):185–186.
   PubMed Web of Science ®Google Scholar
• Bevans SL, Mayo TT, Elewski BE. Safety of secukinumab in hepatitis B virus. J Eur Acad Dermatol Venereol. 2018;32(3):e120–e121.
   PubMed Web of Science ®Google Scholar
• Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):88–97.e5.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Hui RC, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B OR C: a multicentric prospective cohort study. Acta Derm Venereol. 2018;98(9):829–834.
   PubMed Web of Science ®Google Scholar
• Yang C, Cui F, Chen LM, et al. Correlation between Th17 and nTreg cell frequencies and the stages of progression in chronic hepatitis B. Mol Med Rep. 2016;13(1):853–859.
   PubMed Web of Science ®Google Scholar
• Assefa GT, Kaneko S, Oguro H, et al. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient. J Dermatol. 2019;46(3):e112–e113.
   PubMed Web of Science ®Google Scholar
• Diebold M, Müller S, Derfuss T, et al. A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions. Mult Scler Relat Disord. 2019;31:38–40.
   PubMed Web of Science ®Google Scholar
• Nakahara T, Konishi S, Yasukochi Y, et al. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab. J Dermatol. 2019;46(5):e157–e158.
   PubMed Web of Science ®Google Scholar